London
· Delayed Price · Currency is GBP · Price in CAD COSCIENS Biopharma Statistics
Total Valuation
COSCIENS Biopharma has a market cap or net worth of GBP 8.55 million. The enterprise value is -5.47 million.
| Market Cap | 8.55M |
| Enterprise Value | -5.47M |
Important Dates
The next estimated earnings date is Wednesday, March 26, 2025.
| Earnings Date | Mar 26, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +6.18% |
| Shares Change (QoQ) | +39.91% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 3.45M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 0.63 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.32 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 0.26 |
Financial Position
The company has a current ratio of 3.46, with a Debt / Equity ratio of 0.08.
| Current Ratio | 3.46 |
| Quick Ratio | 2.70 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.06 |
| Interest Coverage | -3,624.18 |
Financial Efficiency
Return on equity (ROE) is -100.27% and return on invested capital (ROIC) is -56.49%.
| Return on Equity (ROE) | -100.27% |
| Return on Assets (ROA) | -31.52% |
| Return on Capital (ROIC) | -56.49% |
| Revenue Per Employee | 300,554 |
| Profits Per Employee | -1.44M |
| Employee Count | 12 |
| Asset Turnover | 0.11 |
| Inventory Turnover | 0.39 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -97.89% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -97.89% |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 42.16 |
| Average Volume (20 Days) | 209 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, COSCIENS Biopharma had revenue of GBP 3.61 million and -17.32 million in losses. Loss per share was -10.66.
| Revenue | 3.61M |
| Gross Profit | 3.11M |
| Operating Income | -16.23M |
| Pretax Income | -17.67M |
| Net Income | -17.32M |
| EBITDA | -16.12M |
| EBIT | -16.23M |
| Loss Per Share | -10.66 |
Balance Sheet
The company has 14.92 million in cash and 1.21 million in debt, giving a net cash position of 13.71 million.
| Cash & Cash Equivalents | 14.92M |
| Total Debt | 1.21M |
| Net Cash | 13.71M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 14.93M |
| Book Value Per Share | 4.78 |
| Working Capital | 14.96M |
Cash Flow
In the last 12 months, operating cash flow was -20.29 million and capital expenditures -549,130, giving a free cash flow of -20.84 million.
| Operating Cash Flow | -20.29M |
| Capital Expenditures | -549,130 |
| Free Cash Flow | -20.84M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 86.18% |
| Operating Margin | -449.88% |
| Pretax Margin | -489.90% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
COSCIENS Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.18% |
| Shareholder Yield | -6.18% |
| Earnings Yield | -202.54% |
| FCF Yield | -243.70% |
Stock Splits
The last stock split was on July 21, 2022. It was a reverse split with a ratio of 0.04.
| Last Split Date | Jul 21, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.04 |
Scores
COSCIENS Biopharma has an Altman Z-Score of -0.85. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.85 |
| Piotroski F-Score | n/a |